Eli Lilly reported Q2 earnings and revenue that beat estimates, driven by surging demand for weight loss drug Zepbound and diabetes treatment Mounjaro, while raising its full-year sales outlook.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
Novo Nordisk ha demandado a Eli Lilly en EE.UU. por presunta publicidad engañosa, alegando que Lilly compara sus tratamientos para la obesidad y diabetes con dosis antiguas de Novo Nordisk para mostrar resultados superiores. La disputa se da en la carrera por liderar el creciente mercado de fármacos contra la obesidad.
Many insurance plans are dropping coverage for GLP-1 drugs like Zepbound and Wegovy for weight loss, leaving patients like Deborah Finley struggling to afford them. Experts suggest navigating coverage by checking fine print, filing appeals with doctor support, documenting care, seeking discounts, and being cautious with compounded versions.
O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.
Research shows 12 million people lost coverage for Zepbound and 12 million for Wegovy from 2025 to 2026, with 88% of those who still have coverage facing restrictions. Patients like Meghan Lena, a Massachusetts teacher, describe losing coverage twice within months and being forced to pay $300 monthly for compounded alternatives or face treatment interruption.
